• Corpus ID: 89429333

Immunoterapia topica del carcinoma vescicale con KLH (keyhole limpet hemocyanin): studio controllato di fase 2

@inproceedings{Bassi2002ImmunoterapiaTD,
  title={Immunoterapia topica del carcinoma vescicale con KLH (keyhole limpet hemocyanin): studio controllato di fase 2},
  author={P. F. Bassi and Flavia Longo and R. Spinadin and Veronica De Marco and M. Repele and G. Mostaccio and Alex Ingrassia and Domenica Battaglia and F. Sciobica and R. Bertoloni and F. Gottardo},
  year={2002}
}
Topical immunotherapy, and more precisely BCG, has made considerable steps forward in the topical treatment of superficial bladder cancer. It is therefore important to develop new immunomodulators to work alongside or replace BCG. In this sense, KLH appears promising. The result of a controlled study on patients with carcinoma in-situ is reported. KLH appears active and non-toxic.